China's drug regulator approved Shanghai Fosun Pharmaceutical's (SHA:600196, HKG:2196) clinical trials for its FXS0683 tablets, according to a Saturday filing with the Shanghai bourse.
The drug is indicated for blood cancers, helps prevent tumor growth, the filing said.